Krystal Biotech (KRYS) Net Income Growth (3y) (2019 - 2026)
Krystal Biotech (KRYS) Net Income Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 47.10% |
| 10 | Krystal Biotech | 10.20 Bn | 9.37 Bn | 110.08 Mn | 35.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.53% |
| Dec 31, 2025 | 51.98% |
| Sep 30, 2025 | 46.70% |
| Jun 30, 2025 | 38.70% |
| Mar 31, 2025 | 34.59% |
| Dec 31, 2024 | 59.59% |
| Sep 30, 2024 | 45.53% |
| Jun 30, 2024 | 33.82% |
| Mar 31, 2024 | 26.43% |
| Dec 31, 2023 | 41.50% |
| Sep 30, 2023 | 92.42% |
| Jun 30, 2023 | -68.53% |
| Mar 31, 2023 | -69.78% |
| Dec 31, 2022 | -15.62% |
| Sep 30, 2022 | -67.89% |
| Jun 30, 2022 | -48.19% |
| Mar 31, 2022 | -82.85% |
| Dec 31, 2021 | -37.24% |
| Sep 30, 2021 | -59.37% |
| Jun 30, 2021 | -101.33% |